Analyst Price Targets — INSM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 16, 2026 10:48 am | — | Guggenheim | $230.00 | $146.74 | TheFly | Insmed price target raised to $230 from $227 at Guggenheim |
| April 14, 2026 11:08 am | — | RBC Capital | $216.00 | $151.14 | TheFly | Insmed price target raised to $216 from $212 at RBC Capital |
| April 10, 2026 9:32 am | — | Raymond James | $200.00 | $155.80 | TheFly | Insmed initiated with an Outperform at Raymond James |
| April 8, 2026 12:38 pm | — | Mizuho Securities | $202.00 | $160.18 | TheFly | Insmed price target lowered to $202 from $206 at Mizuho |
| March 26, 2026 3:13 pm | — | H.C. Wainwright | $245.00 | $147.60 | TheFly | Insmed price target raised to $245 from $230 at H.C. Wainwright |
| February 24, 2026 11:49 am | — | Mizuho Securities | $204.00 | $159.03 | TheFly | Insmed price target lowered to $204 from $211 at Mizuho |
| February 20, 2026 1:15 pm | — | Morgan Stanley | $166.00 | $158.80 | TheFly | Insmed price target raised to $166 from $162 at Morgan Stanley |
| February 20, 2026 11:27 am | Tiago Fauth | Wells Fargo | $208.00 | $161.00 | TheFly | Insmed price target lowered to $208 from $234 at Wells Fargo |
| February 19, 2026 6:38 pm | — | Stifel Nicolaus | $205.00 | $159.88 | TheFly | Insmed price target lowered to $205 from $212 at Stifel |
| February 19, 2026 12:18 pm | Graig Suvannavejh | Mizuho Securities | $211.00 | $151.11 | TheFly | Insmed price target lowered to $211 from $212 at Mizuho |
Latest News for INSM
Assetmark Inc. boosted its holdings in Insmed, Inc. (NASDAQ: INSM) by 12.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,732 shares of the biopharmaceutical company's stock after buying an additional 4,438 shares during the period. Assetmark Inc.'s
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on Thursday as mixed reports on the success of the ships passing through the Strait of Hormuz rolled in, stocks gained momentum as the... Here Are Friday's Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike,…
INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.
Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INSM.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.